Premium
P4‐288: Efficacy, safety and tolerability of rivastigmine patch 13.3 mg/24 h (15 cm2) versus 4.6 mg/24 h (5 cm2) in patients with severe Alzheimer's disease: Results of the ACTivities of daily living and cognitION (ACTION) study
Author(s) -
Farlow Martin,
Meng Xiangyi,
Rensch Scott,
Somogyi Monique
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.08.069
Subject(s) - tolerability , rivastigmine , clinical global impression , medicine , transdermal patch , demographics , adverse effect , randomized controlled trial , dementia , transdermal , disease , pharmacology , donepezil , placebo , alternative medicine , demography , pathology , sociology